Stock OCUP OCUPHIRE PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Ocuphire Pharma, Inc.

Equities

OCUP

US67577R1023

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
1.85 USD +12.80% Intraday chart for Ocuphire Pharma, Inc. +20.52% -38.54%
Apr. 11 Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment MT
Apr. 11 Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
AQ
Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment
MT
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
AQ
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc
CI
Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study
CI
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
AQ
Alliance Global Partners Cuts Price Target on Ocuphire Pharma to $20 From $24, Maintains Buy Rating
MT
Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
AQ
Ocuphire Pharma to Present in the BIO CEO and Investor Conference
AQ
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
AQ
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Ocuphire Pharma Appoints CFO, Science Chief
MT
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
AQ
Ocuphire Pharma, Inc. Announces Appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer
CI
Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer
CI
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
AQ
Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy
CI
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Ocuphire Pharma, Inc. Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity Under Dim Light Conditions
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCUP Stock
  4. News Ocuphire Pharma, Inc.